A Phase 2a, Open-label, Multiple Dose, Safety, Pharmacokinetic and Biomarker Study of PTl-125 in Mild-to-moderate Alzheimer's Disease Patients
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2018
At a glance
- Drugs PTI-125 (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Pharmacokinetics
- Sponsors Pain Therapeutics
- 18 Nov 2018 Status changed from planning to recruiting.
- 20 Sep 2018 New trial record
- 15 Aug 2018 According to a Pain Therapeutics media release, the company expects to initiate the study in Q4 2018.